We have performed a comprehensive meta-analysis of the most commonly prescribed GLP-1 RAs based on the largest pool of GLP-1 RA trials for patients with T2DM and NAFLD to date. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.